3차 병원 류마티스 관절염 환자에서 항종양괴사인자 제제 치료 후 임상반응 및 관찰 평가 분석

• 영문명: Clinical Responses and Follow-up Evaluation after Anti-TNF Treatment in Patients with Rheumatoid Arthritis at a Tertiary-care Hospital
• 발행기관: 대한약학회
• 저자명: 박선희(Sun Hee Park) 최인(In Choe) 최은주(Eun Joo Choi)
• 간행물 정보: 『약학회지』제64권 제1호(2020년), 28~38쪽, 전체 11쪽
• 주제분류: 의약학 > 기타의약학
• 파일형태: PDF
• 발행일자: 2020.02.29

영문 초록

Rheumatoid arthritis (RA) is a chronic inflammatory disease that causes joint damage and bone erosion. Antitumor necrosis factor (anti-TNF) agents are first-line biological Disease-Modifying Anti-rheumatic Drugs (DMARDs), which can reduce the disease activity of RA. The objective of this study is to evaluate and observe the clinical responses and parameters following anti-TNF administration. We analysed the medical records of patients who were administered anti-TNF agent for RA, from September 2012 to August 2015, retrospectively. The clinical responses (ESR, CRP, swollen joint count, tender joint count) and adverse effect monitoring factors (AST, ALT, white blood cell count, hemoglobin, neutrophils count, platelet count, serum creatinine) were observed before the drug administration, and follow-up observation were also made at 3, 9, and 15-month post-administration. 104 patients of 306 patients were selected based on inclusion and exclusion criteria, and were administered etanercept (n=38), adalimumab (n=46), and infliximab (n=20). After 3 months, the clinical response significantly decreased, regardless of the type of anti-TNF agents used, and the levels were maintained up to 15 months (p<0.05). Platelet, WBC and neutrophils count decreased after 3 months of anti-TNF agent administration, regardless of the type of anti-TNF agents used, and the levels were maintained up to 15 months (p<0.05). Serum creatinine showed constant increase over the course of 15 months. Further related multi-institutional prospective studies are needed to confirm and optimize the study.

목차

서 론(Introduction)

연구 방법(Research Methods)

결 과(Results)

고 찰(Discussion)

결 론(Conclusion)

Conflict of Interest

References

키워드

Anti-TNF agents adalimumab clinical responses etanercept follow-up evaluation infliximab Rheumatoid Arthritis